Posted on Leave a comment

Ziopharm Oncology, Inc

It is developing Ad-RTS-hIL-12 plus veledimex, which is in Phase 2 clinical trial, to treat patients with recurrent glioblastoma multiforme in adults. The company is also developing chimeric antigen receptor T-cell and T-cell receptor T-cell therapies. Learn everything you need to know about successful options trading with this three-part video course. Click the Predict button to answer the prediction request. Best predictor for any stock is listed at the stock pages. featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Over the last 5 years, ZIOP has generated revenue in the amount of $-28.80% with earnings coming in at 28.00%. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 0.

What Analysts Think About Ziopharm Oncology, Inc

On average, Wall Street analysts predict that Ziopharm Oncology’s share price could reach $6.00 by Nov 12, 2021. The average Ziopharm Oncology stock price prediction forecasts a potential upside of 66.67% from the current ZIOP share price of $3.60. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis.

On corrections down, there will be some support from the lines at $3.46 and $2.97. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence . Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, January 20, 2021, and so far it has fallen -4.26%. Further fall is indicated until a new bottom pivot has been found. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Search Investors Hangout

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding Buy stocks ZIOP and currently available. At the moment, there are 152.95M shares of ZIOPHARM Oncology, Inc. outstanding.

Buy stocks ZIOP

In the past six months, we’ve seen a change that works out to 97.81% from the stock. Throughout the last 7 days, ZIOP has generated a change in Buy stocks ZIOP value amounting to -3.63%. View the Terms of Use.NYSE/AMEX data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless indicated.

Forecast Return On Assets

5 brokerages have issued 1-year price targets for ZIOPHARM Oncology’s stock. On average, they anticipate ZIOPHARM Oncology’s share price to reach $6.30 in the next twelve months. This suggests a possible upside of 78.0% from the stock’s current price. View analysts’ price targets for ZIOPHARM Oncology or view Wall Street analyst’ top-rated stocks. The ZIOPHARM Oncology Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.

Buy stocks ZIOP

Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, ZIOP has a float of 152.95M. Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead.

Ziopharm Oncology Inc (ziop) Npv

To see all exchange delays and terms of use, please see disclaimer. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

Information is provided ‘as-is’ and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.


1,448 employees have rated ZIOPHARM Oncology CEO Doug Parker on Doug Parker has an approval rating of 60% among ZIOPHARM Oncology’s employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Earnings for ZIOPHARM Oncology are expected to decrease in the coming year, from ($0.36) to ($0.40) per share. Only 2.30% of the stock of ZIOPHARM Oncology is held by insiders. ZIOPHARM Oncology has only been the subject of 1 research reports in the past 90 days.

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.27. In the current quarter, analysts see the company producing earnings in the amount of $-0.08.

Stocks Open Lower, Dow Drops 150+ Points

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. Raymond James is very positive to ZIOP and gave it a “Outperform” rating on November 06, 2020. ZIOPHARM Oncology Inc finds support from accumulated volume at $3.51 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments.

Leave a Reply

Your email address will not be published. Required fields are marked *